Slovenia’s Krka started a new production of active pharmaceutical ingredients

• Automation & Robotics • News • South-East European INDUSTRIAL Мarket - issue 3/2015

The Slovenian drug manufacturer Krka officially announced it has opened a new facility for the production of active pharmaceutical ingredients in Krsko, a town in the eastern part of the country.
The 85 million euro ($95,3 million) Sinteza 1 plant should provides new capabilities for managing the entire process from development to production of raw materials and finished products, Krka said in a statement.

Krka’s basic line of business is the production and sale of prescription pharmaceuticals, non-prescription products and animal health products.

The company’s focus is on the development of high-quality own-brand generic pharmaceuticals, which offer added value, and are marketed under Krka’s own brands.

The drug maker is investing 165 million euro this year after investing 174 million euro in 2014.
Krka’s consolidated net profit rose 5% to 112,3 million euro in the first half of 2015 when consolidated sales were nearly flat at 599,9 million euro.

Keywords: Krka, active pharmaceutical ingredients, Sinteza 1, generic pharmaceuticals, animal health products